Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 52

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Malignant melanoma

Not recruiting

Study on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Immunocore Limited

Keratosis follicular

Not recruiting

Study on Dantrolene Sodium for Treating Darier Disease in Affected Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dantrolene Sodium
  • Sponsor:Karolinska University Hospital

Epidermolysis bullosa

Not recruiting

Study on the Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells for Patients with Epidermolysis Bullosa

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded
  • Sponsor:Masarykova Univerzita

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Dermatomyositis

Not recruiting

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Metastatic malignant melanoma

Not recruiting

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Universitaetsklinikum Erlangen AöR

Squamous cell carcinoma of skin+1

Not recruiting

Study of L19IL2 and L19TNF for Patients with Advanced Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Not Eligible for Surgery or Radiation

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:NAVENIBART
  • Sponsor:Astria Therapeutics Inc.

Neurofibromatosis

Not recruiting

Study on the Effect of Food on Selumetinib in Adolescents with Neurofibromatosis Type 1 Plexiform Neurofibromas

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Alopecia areata

Not recruiting

Study on Rezpegaldesleukin for Treating Severe Alopecia Areata in Adults

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.